Tempus xR

Search documents
Tempus Ai,Inc.(TEM) - 2025 Q2 - Earnings Call Presentation
2025-08-08 12:00
Financial Performance - Revenue for Q2 2025 increased by 896% year-over-year to $3146 million from $1660 million in Q2 2024[52, 55] - Genomics revenue reached $2418 million, a 1153% increase compared to Q2 2024[55] - Data and Services revenue totaled $728 million, growing 357% year-over-year, with Insights (data licensing) growing 407%[55] - Gross profit improved by 1583% year-over-year, reaching $1950 million in Q2 2025[52, 55] - Adjusted EBITDA improved by 821%, with a loss of $(56) million in Q2 2025 compared to $(312) million in Q2 2024[52, 55] Genomics Business - Oncology testing (Tempus Genomics) revenue was $1332 million, up 329% year-over-year, with approximately 26% volume growth[55] - Hereditary testing (Ambry Genetics) contributed $973 million of revenue, up 336% year-over-year on a pro forma basis, with approximately 32% volume growth[55] - Average reimbursement per hereditary test was $760 in Q2 2025[24] Data and AI - Total Remaining Contract Value for Data and Services was >$940 million at the end of 2024[39] - Data Licensing Retention was ~140% at the end of 2024[39] - Tempus has >350 petabytes of rich multimodal healthcare data[12, 37]
Tempus Ai,Inc.(TEM) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:20
Financial Performance - Revenue increased by 754% year-over-year to $2557 million in Q1 2025[56] - Genomics revenue reached $1938 million, an 889% increase compared to Q1 2024[56] - Data and services revenue totaled $619 million, growing 432% year-over-year, with Insights (data licensing) growing 580%[56] - Gross profit improved by 998% year-over-year to $1552 million in Q1 2025[56] - Adjusted EBITDA improved from $(439) million in Q1 2024 to $(162) million in Q1 2025[56] - The company anticipates approximately $300 million, or ~24%, of its annual revenue guidance in the second quarter[66] Genomics - Oncology testing (legacy Tempus clinical) revenue increased by 310% year-over-year to $1190 million, driven by ~20% volume growth[56] - Hereditary (legacy Ambry Genetics) revenue was $635 million, representing ~23% unit growth year-over year[56] - Oncology NGS tests delivered increased from 62700 in Q1 2024 to 75000 in Q1 2025[21] - Hereditary tests delivered were approximately 63500 in Q1 2024 and increased to approximately 78000 in Q1 2025[23] Data and AI - Total Remaining Contract Value (TCV) for Data and Services exceeded $940 million at the end of 2024[39] - Data Licensing Retention was approximately 140% at the end of 2024[39] - The company has >300 petabytes of rich multimodal healthcare data[12]